Methods of using BTL-II proteins

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Immunex Corporation patent solves the following problem:

Modulation of an immune or inflammatory response can be a valuable tool to control various types of diseases including autoimmune diseases, diseases characterized by abnormal inflammation and / or immune response, and infections . In treating diseases characterized by abnormal inflammation and / or immune responses, such as inflammatory bowel disease and autoimmune or inflammatory diseases, modulation of an immune response is desirable. In other situations, for example when the vaccine to a patient to give immunity to an infectious disease, stimulation of an immune response is desirable. In the case of vaccines, adjuvants on an immune response to a coadministered antigen can be valuable in providing long term protection against the disease. Particularly lacking in the art is the adjuvants capable of stimulating a mucosal immune response. A mucosal immune response, as opposed to a systemic immune response, is valuable because it attacks an infection with a very common point of entry, that is, to a mucosal surface. The present invention addresses these needs in the art by providing therapeutic agents for the diagnosis and treatment of diseases characterized by inadequate and / or abnormal inflammation and / or immune response and therapeutic agents that act as adjuvants to stimulate an immune response, particularly a mucosal immune response.

Our analysis of this patent is as follows:

Immunex Corporation’s patent US 8173603 B2 deals with Methods of using BTL-II proteins.
invention provides isolated BTL-II protein, nucleic acid, antibody, enemies, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods of using the compositions of the invention given. For example, the composition of the invention can be used for diagnosis and treatment of inflammatory intestinal diseases and for the development of a mucosal immune response to an antigen.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anhdyrous lactose agglomerates and the preparation thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Campina Nederland Holding B.V. patent solves the following problem:

Lactose is widely used as a filler, filler, binder or diluent in tablets and capsules, and to a more limited extent on the lyophilized products, baby food formula, and as a carrier dry powder inhaler. Worldwide, whispered put the needs of their lactose monographs in the identity and purity of pharmaceutical grade lactose, thereby distinguishing between lactose monohydrate and anhydrous lactose. According to these medicines, anhydrous lactose must have a water content of at most 1 wt%, and for that reason particularly useful as excipient in moisture-sensitive applications.

Our analysis of this patent is as follows:

Campina Nederland Holding B.V.’s patent US 8173173 B2 deals with Anhdyrous lactose agglomerates and the preparation thereof.
The invention relates to a process for the preparation of anhydrous lactose agglomerates, said process comprising (i) subjecting essentially anhydrous lactose primary particles comprising at least 60 wt% lactose crystals in a granulator to a wet step granulation in a temperature range of 30-100 C. using a binder solution, which granulation mass subjected to dry for at least part of steps granulation, and (ii ) after dry granulation mass. The anhydrous lactose agglomerates comprising at least 50 wt% -lactose crystallites and a total water content in the range of 0-1.0 wt%, required by the standards laid down by the whispers anhydrous lactose excipients. These agglomerates combine with excellent compactibility and flowability properties and particularly useful as excipient in moisture-sensitive applications.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.